Novocure Total Operating Expenses vs Total Other Income Expense Net Analysis
| NVCR Stock | USD 21.51 0.66 2.98% |
Novocure financial indicator trend analysis is infinitely more than just investigating Novocure recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novocure is a good investment. Please check the relationship between Novocure Total Operating Expenses and its Total Other Income Expense Net accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novocure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.
Total Operating Expenses vs Total Other Income Expense Net
Total Operating Expenses vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novocure Total Operating Expenses account and Total Other Income Expense Net. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Novocure's Total Operating Expenses and Total Other Income Expense Net is -0.04. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Novocure, assuming nothing else is changed. The correlation between historical values of Novocure's Total Operating Expenses and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Novocure are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Total Operating Expenses i.e., Novocure's Total Operating Expenses and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | -0.04 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Total Other Income Expense Net
Most indicators from Novocure's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novocure current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novocure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.As of 05/17/2024, Selling General Administrative is likely to drop to about 87.6 M. In addition to that, Tax Provision is likely to drop to about 9.1 M
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.4M | 3.3M | 3.3M | 3.2M | Depreciation And Amortization | 10.3M | 10.6M | 11.0M | 7.8M |
Novocure fundamental ratios Correlations
Click cells to compare fundamentals
Novocure Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novocure fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 479.4M | 1.1B | 1.1B | 1.2B | 1.1B | 651.0M | |
| Short Long Term Debt Total | 163.6M | 444.2M | 575.2M | 584.3M | 596.2M | 626.1M | |
| Other Current Liab | (1K) | 35.7M | (17.8M) | (18.0M) | (16.2M) | (15.4M) | |
| Total Current Liabilities | 86.3M | 113.6M | 142.6M | 158.8M | 179.1M | 188.1M | |
| Total Stockholder Equity | 217.8M | 476.5M | 410.5M | 441.2M | 362.5M | 279.7M | |
| Other Liab | 11.7M | 17.6M | 11.2M | 7.4M | 8.5M | 8.8M | |
| Net Tangible Assets | 217.8M | 476.5M | 410.5M | 441.2M | 507.3M | 267.8M | |
| Property Plant And Equipment Net | 34.6M | 41.6M | 53.9M | 69.0M | 97.7M | 102.6M | |
| Net Debt | (13.8M) | 209.5M | 366.4M | 468.9M | 355.4M | 373.2M | |
| Retained Earnings | (650.9M) | (631.1M) | (685.9M) | (778.5M) | (985.5M) | (936.2M) | |
| Accounts Payable | 36.9M | 53.6M | 72.6M | 85.2M | 94.4M | 99.1M | |
| Cash | 177.3M | 234.7M | 208.8M | 115.3M | 240.8M | 164.9M | |
| Non Current Assets Total | 39.5M | 52.5M | 66.0M | 80.1M | 111.7M | 117.3M | |
| Non Currrent Assets Other | 4.9M | 10.9M | 12.1M | 11.2M | 14.0M | 14.7M | |
| Other Assets | 4.9M | 10.9M | 12.1M | 11.2M | 12.8M | 13.5M | |
| Long Term Debt | 149.4M | 429.9M | 562.2M | 565.5M | 568.8M | 597.3M | |
| Cash And Short Term Investments | 326.1M | 842.6M | 937.7M | 969.4M | 910.6M | 518.3M | |
| Net Receivables | 88.1M | 117.9M | 110.6M | 112.2M | 77.1M | 63.0M | |
| Common Stock Shares Outstanding | 97.2M | 108.9M | 103.4M | 104.7M | 106.4M | 96.1M | |
| Short Term Investments | 148.8M | 607.9M | 728.9M | 854.1M | 669.8M | 353.5M | |
| Liabilities And Stockholders Equity | 479.4M | 1.1B | 1.1B | 1.2B | 1.1B | 651.0M | |
| Non Current Liabilities Total | 175.3M | 461.8M | 586.4M | 591.7M | 604.5M | 634.7M | |
| Inventory | 23.7M | 27.4M | 24.4M | 29.4M | 38.2M | 23.2M | |
| Other Current Assets | 1K | 11.5M | 807K | 6.7M | 8.5M | 4.5M | |
| Other Stockholder Equity | 871.4M | 1.1B | 1.1B | 1.2B | 1.4B | 916.6M | |
| Total Liab | 261.7M | 575.5M | 729.0M | 750.5M | 783.6M | 822.8M | |
| Total Current Assets | 439.9M | 999.4M | 1.1B | 1.1B | 1.0B | 607.6M | |
| Accumulated Other Comprehensive Income | (2.8M) | (3.8M) | (3.2M) | (2.4M) | (5.5M) | (5.2M) | |
| Property Plant Equipment | 34.6M | 11.4M | 53.9M | 32.7M | 37.6M | 22.9M | |
| Retained Earnings Total Equity | (650.9M) | (631.1M) | (685.9M) | (778.5M) | (700.6M) | (735.6M) | |
| Current Deferred Revenue | 11.8M | 17.8M | 17.8M | 18.0M | 16.2M | 13.4M | |
| Long Term Debt Total | 149.5M | 429.9M | 562.2M | 565.5M | 650.3M | 682.9M | |
| Capital Surpluse | 871.4M | 1.1B | 1.1B | 1.2B | 1.4B | 1.0B | |
| Non Current Liabilities Other | 182K | 31.9M | 166K | 148K | 18K | 17.1K | |
| Net Invested Capital | 367.2M | 906.4M | 972.7M | 1.0B | 931.3M | 731.9M | |
| Net Working Capital | 353.6M | 885.8M | 930.9M | 952.8M | 855.3M | 696.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novocure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.Note that the Novocure information on this page should be used as a complementary analysis to other Novocure's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Novocure Stock analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Novocure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novocure. If investors know Novocure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novocure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share (1.81) | Revenue Per Share 4.922 | Quarterly Revenue Growth 0.134 | Return On Assets (0.11) |
The market value of Novocure is measured differently than its book value, which is the value of Novocure that is recorded on the company's balance sheet. Investors also form their own opinion of Novocure's value that differs from its market value or its book value, called intrinsic value, which is Novocure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novocure's market value can be influenced by many factors that don't directly affect Novocure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novocure's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novocure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novocure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.